Trade DiaMedica Therapeutics Inc. - DMAC CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.099
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 8.0299
• Open: 7.5901
• 1-Year Change: 8.13%
• Day's Range: 7.5205 - 8.0499

Trade DiaMedica Therapeutics Inc. - DMAC

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, DiaMedica Therapeutics Inc revenues was not reported. Net loss increased 11% to $13.6M. Higher net loss reflects General and administrative - Balancing increase of 23% to $3.8M (expense), Research and development - Balancing increase of 7% to $8.3M (expense), Governmental assistance research incen decrease from $205K (income) to $0K.